NAS:ATAI (Germany)
Business Description
ATAI Life Sciences NV
c/o Mindspace, Krausenstrasse 9-10, Berlin, BB, DEU, 10117
Compare
Compare
Traded in other countries / regions
9VC.Germany
•
ATAI.Mexico
•
ATAI.USA
Description
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. Its product candidates include COMP360/Psilocybin therapy, PCN-101/R-ketamine, RL-007/Compound, DMX-1002/Ibogaine, GRX-917/Deuterated etifoxine, VLS-01/DMT, EMP-01/MDMA derivative, RLS-01/Salvinorin A, KUR-101/Deuterated Mitragynine, and DMX-1001/Noribogaine. The business operates geographically in two regions being the United States and Germany.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 461.95 | |||||
| Equity-to-Asset | 0.9 | |||||
| Debt-to-EBITDA | -0.01 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | N/A/9 | |||||
| Altman Z-Score | 13.12 | |||||
| Beneish M-Score | -2.66 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History |
|---|
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 70.83 | |||||
| 9-Day RSI | 66.81 | |||||
| 14-Day RSI | 63.45 | |||||
| 6-1 Month Momentum % | -27.97 | |||||
| 12-1 Month Momentum % | -68.8 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 15.79 | |||||
| Quick Ratio | 15.79 | |||||
| Cash Ratio | 15.16 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History |
|---|
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -32013.91 | |||||
| Net Margin % | -41404.23 | |||||
| ROE % | -58.26 | |||||
| ROA % | -53.11 | |||||
| ROIC % | -407.81 | |||||
| ROC (Joel Greenblatt) % | -84823.18 | |||||
| ROCE % | -43.11 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 1142.51 | |||||
| PB Ratio | 2.13 | |||||
| Price-to-Tangible-Book | 2.13 | |||||
| EV-to-EBIT | -2.5 | |||||
| EV-to-Forward-EBIT | -2.27 | |||||
| EV-to-EBITDA | -2.5 | |||||
| EV-to-Forward-EBITDA | -2.27 | |||||
| EV-to-Revenue | 803.8 | |||||
| EV-to-FCF | -5.6 | |||||
| Price-to-Net-Current-Asset-Value | 2.36 | |||||
| Price-to-Net-Cash | 2.47 | |||||
| Earnings Yield (Greenblatt) % | -39.87 |
Guru Trades
See DetailsEMBED
SAVE
Insider Trades
See DetailsEMBED
SAVE
Gurus Latest Trades with NAS:ATAI
Executives
EMBED
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 0.496 | ||
| EPS (TTM) ($) | -1.44 | ||
| Beta | 0 | ||
| Volatility % | 46.47 | ||
| 14-Day RSI | 63.45 | ||
| 14-Day ATR ($) | 0.289991 | ||
| 20-Day SMA ($) | 4.145 | ||
| 12-1 Month Momentum % | -68.8 | ||
| 52-Week Range ($) | 2.95 - 17.9 | ||
| Shares Outstanding (Mil) | 160.73 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 9999 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
ATAI Life Sciences NV Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||